Skip to content

US · TNYA · BIOTECHNOLOGY

Tenaya Therapeutics, Inc. (TNYA) intrinsic value and stock valuation

$0.29as of 2026-11-21 · Mkt cap 157.71M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tenaya Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values TNYA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TNYA’s statements →

Tenaya Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 tenayatherapeutics.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-90.6M
20192025
Free cash flow
-$-68.88M
20192025
Total equity
$123.3M-2.4% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-93.33M-$-115.95M-$-131.19M-$-125.62M-$-72.81M
Net income-$-90.6M-$-111.13M-$-124.08M-$-123.67M-$-72.72M
EPSd-$-592.27K-$-1.31M-$-1.68M-$-2.76M-$-1.76M
Operating cash flow-$-68.26M-$-90.5M-$-102.07M-$-104.42M-$-60.81M
Capital expenditure-$-620K-$-1.02M-$-1.24M-$-20.63M-$-25.12M
Free cash flow-$-68.88M-$-91.53M-$-103.31M-$-125.05M-$-85.93M
Total assets$146.9M$119.9M$170.5M$278.9M$316.7M
Total debt$10.8M$13.6M$12.4M$15.1M$15.7M
Net debt-$-89.72M$9.29M-$-33.26M-$-80.17M-$-22.43M
Total equity$123.3M$92.9M$139.4M$243.4M$278.5M
Cash and short-term investments$100.6M$61.5M$104.6M$186.5M$251.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$8.44M$8.47M$8.69M$8.71M$4.03M
Gross profit-$-8.44M-$-8.47M-$-8.69M-$-8.71M-$-4.03M
Research and development expenses$68.6M$86.7M$98M$94.5M$54.4M
Selling, general and administrative expenses$24.7M$20.7M$24.5M$22.4M$14.4M
Other expenses-$-8.44M$0.00$0.00$0.00$0.00
Operating expenses$84.9M$107.5M$122.5M$116.9M$68.8M
Cost and expenses$93.3M$116M$131.2M$125.6M$72.8M
Interest income$2.68M$4.74M$7.06M$1.95M$110K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$8.44M$8.47M$8.69M$8.71M$4.03M
Ebitda-$-82.16M-$-102.66M-$-115.4M-$-114.95M-$-68.7M
Operating income-$-93.33M-$-115.95M-$-131.19M-$-125.62M-$-72.81M
Total other income/expenses, net$2.73M$4.82M$7.11M$1.96M$90K
Income before tax-$-90.6M-$-111.13M-$-124.08M-$-123.67M-$-72.72M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-90.6M-$-111.13M-$-124.08M-$-123.67M-$-72.72M
Weighted average shares outstanding$153M$84.8M$73.8M$44.8M$41.3M
Weighted average diluted shares outstanding$153M$84.8M$73.8M$44.8M$41.3M
Balance sheet
20252024202320222021
Cash and short-term investments$100.6M$61.5M$104.6M$186.5M$251.3M
Net receivables$0.00$0.00$0.00$2.25M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$105.6M$67.4M$111.6M$193.8M$255.4M
Property, plant and equipment, net$37.1M$47.8M$53.3M$62.7M$54.7M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$420K$0.00$0.00$17.7M$550K
Total non-current assets$41.3M$52.6M$58.9M$85.2M$61.3M
Total assets$146.9M$119.9M$170.5M$278.9M$316.7M
Accounts payable$3.58M$5.16M$5.63M$9.58M$10.7M
Short-term debt$3.02M$2.78M$4.32M$4.01M$1.99M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$15.4M$16M$22.7M$24.3M$21.8M
Long-term debt$7.81M$10.8M$8.11M$11.1M$13.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$8.22M$11.1M$8.36M$11.3M$16.4M
Capital lease obligations$3.02M$10.8M$12.4M$15.1M$13.7M
Total liabilities$23.7M$27.1M$31.1M$35.6M$38.1M
Common stock$20K$10K$10K$10K$0.00
Retained earnings-$-605.01M-$-514.41M-$-403.28M-$-279.2M-$-155.53M
Accumulated other comprehensive income (loss)$0.00$30K-$-110K-$-380K-$-140K
Total equity$123.3M$92.9M$139.4M$243.4M$278.5M
Total investments$420K$57.1M$59M$109M$213.7M
Total debt$10.8M$13.6M$12.4M$15.1M$15.7M
Net debt-$-89.72M$9.29M-$-33.26M-$-80.17M-$-22.43M
Cash flow statement
20252024202320222021
Net income-$-90.6M-$-111.13M-$-124.08M-$-123.67M-$-72.72M
Depreciation and amortization$8.85M$8.47M$8.69M$6.47M$2.96M
Stock-based compensation$13.1M$16.5M$15.3M$11.5M$2.95M
Change in working capital-$-2.46M-$-7.93M-$-5.65M-$-850K$4.74M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.43M-$-580K-$-3.28M$1.66M$8.6M
Net cash provided by operating activities-$-68.26M-$-90.5M-$-102.07M-$-104.42M-$-60.81M
Investments in property, plant and equipment-$-620K-$-1.02M-$-1.24M-$-20.63M-$-25.12M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$56.1M$1.13M$48.7M$83.7M-$-238.56M
Common stock issued$108.4M$46.8M$3.87M$77.4M$188.5M
Common stock repurchased$0.00$0.00$0.00$0.00-$-10K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$108.4M$47.8M$4.05M$77.8M$209M
Net change in cash$96.2M-$-41.62M-$-49.31M$57M-$-90.41M
Cash at end of period$101M$4.74M$46.4M$95.7M$38.7M
Operating cash flow-$-68.26M-$-90.5M-$-102.07M-$-104.42M-$-60.81M
Capital expenditure-$-620K-$-1.02M-$-1.24M-$-20.63M-$-25.12M
Free cash flow-$-68.88M-$-91.53M-$-103.31M-$-125.05M-$-85.93M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tenaya Therapeutics, Inc.

        Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

        CEO
        Faraz Ali
        Employees
        70
        Beta
        2.84

        Explore

        Frequently asked questions

        What is the intrinsic value of Tenaya Therapeutics, Inc. (TNYA)?

        InvestorsCraft does not currently publish an intrinsic value for TNYA. How the IC value is calculated.

        Is TNYA undervalued?

        InvestorsCraft does not publish an undervaluation signal for TNYA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.